Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00265109
Status:
COMPLETED
Last Update Posted:
2019-08-29
First Post:
2005-12-12
Brief Title:
Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder
Sponsor:
Butler Hospital
Organization:
Butler Hospital
Study Overview
Official Title:
Open-Label Study of Levetiracetam in Body Dysmorphic Disorder
Status:
COMPLETED
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the usefulness of a medication Levetiracetam for people with body dysmorphic disorder
Detailed Description:
Body dysmorphic disorder BDD a perceived defect in appearance eg a large nose or facial scarring is a relatively common disorder that causes marked distress and impairment in functioning Recent data suggests that adults with BDD may respond to serotonin reuptake inhibitors SRIs however response to SRIs is often only partial About one third of patients do not respond to an SRI Furthermore patients may stop taking SRIs because of side effects eg sexual side effects For these reasons additional monotherapy and SRI augmentation strategies are greatly needed
Levetiracetam is primarily used as an antiseizure medication and has a wider safety margin than other antiepileptics Preliminary scientific studies may suggest that it may be helpful for certain psychiatric symptoms and disorders In the present study we propose to obtain pilot data on 1 levetiracetam monotherapy and 2 levetiracetam augmentation of SRIs in patients with BDD
Levetiracetam is primarily used as an antiseizure medication and has a wider safety margin than other antiepileptics Preliminary scientific studies may suggest that it may be helpful for certain psychiatric symptoms and disorders In the present study we propose to obtain pilot data on 1 levetiracetam monotherapy and 2 levetiracetam augmentation of SRIs in patients with BDD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None